Skip to main content

Table 11 Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9th dose of DMSA in Phase 1) and Changes in Glutathione (Dglut).

From: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results

  Adjusted R2 P-value Equation Most significant variables
Change in PDD-BI (n = 20) 0.75 0.0006 10.25 -2.48Pb9 +0.169Sn9 +113.5Tl9 -119.1Sb9 - 1.199As9 +0.726Al9 - 0.0608DGlut Tl9**, As9**, DGlut**, Pb9*, Sb9*
Change in ATEC (n = 20) 0.44 0.006 9.41 -0.663Pb9 -8.80Hg9- 0.352As9 Hg9**, As9*
Change in SAS (n = 18) 0.57 0.002 -1.01 +0.0985Pb9- -0.00169DGlut Tl9**, Pb9*, DGlut*
Change in ADOS (comm.. + social) (n = 20) 0.28 0.02 -1.91+00.0472As9 - 0.0877Al9 As9*, Al9*
  1. This is the same analysis as Table 10, except it is for the 7-round group only, resulting in much better regression fit and much greater significance in all cases. This demonstrates that the changes in the 7-round group are much better predicted by their excretion of heavy metals and change in glutathione.